Full Press Release Details
Tenon Medical Announces Pricing of At-The-Market
~ Strategically Placed PIPE With Industry Supportive
LOS GATOS, CA / ACCESS Newswire
/ November 11, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care
for patients suffering with certain sacro-pelvic disorders, today announced the pricing of an at-the-market private investment in public
equity (the "PIPE") financing with several accredited investors for total gross proceeds of $2,850,000.
The PIPE is designed to provide accretive
capital through participation from strategic industry partners and members of Tenon's management team. The Company believes that this
alignment underscores the confidence and commitment of key stakeholders in Tenon's long-term vision and growth strategy.
Under the terms of securities
purchase agreements, dated September 10, 2025 between the Company and the applicable investors, the Company will issue, an aggregate
of 2,217,904 shares of common stock (the "Issued Shares") and warrants (the "PIPE Warrants") to purchase
2,217,904 shares of common stock at a combined offering price of $1.285 per share of common stock and warrant to purchase one share
of common stock. The PIPE Warrants have a strike price of $1.16 per share, with an expiration date of 3 years from the date of
issuance. The Issued Shares and the shares underlying PIPE Warrants will be entitled to customary resale registration rights. The
closing of the PIPE is subject to customary closing conditions for financing of this nature.
The gross proceeds from PIPE are expected
to be $2.85 million. The Company intends to use the PIPE proceeds for working capital and general corporate purposes. Proceeds from the
PIPE will support Tenon Medical's upcoming product launches, expansion of commercial operations, advancement of clinical studies, and
continued investment in core business operations.
The securities sold in the PIPE have
not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws
and accordingly may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an
applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute
an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.
About Tenon Medical, Inc.
Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive
approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes
through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis.
The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular
structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon
is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2)
Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.
The Tenon Medical logo shown above, and Catamaran ,
PiSIF , CAT PiSIF , ETAD , Posterior Inferior Sacroiliac Fusion , CAT SIJ Fusion System , Catamaran SIJ Fusion System ,
Catamaran Inferior Posterior Fusion System , Catamaran Transfixation Fusion System , Catamaran Transfixation Fusion Device ,
SImmetry are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical,
This press release contains "forward-looking
statements," which are statements related to events, results, activities, or developments that Tenon expects, believes, or anticipates
will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates,"
"hopes," "projects," "plans," "expects," "seek," "believes," "see,"
"should," "will," "would," "target," "aims," and similar expressions and the negative
versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments
and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements
are inherently uncertain, and actual results may differ materially from assumptions, estimates or expectations reflected or contained
in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to
be materially different than those expressed in our forward-looking statements, please review our Annual Report on 10-K and other reports
on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained
in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements
to reflect new information or future events or otherwise unless required by law.
View the original press release
11/11/2025 8:00:00 AM